NorthWest Biotherapeutics Inc (NWBO)

[gnawkz]

Hi Flip, thanks for the response. That actually answered another question I was researching, but not the main one that was asked. Though I very much appreciate it.

For my original question, I was more interested in what requirements would allow the DMC to end a trial early due to efficacy.

I was speculating that since a "cross over" branch was built into the DCVax-L trial, the DMC would never end the trial early as there is no moral justification for it. Patients whose condition has worsened would still have access to DCVax-L unlike other trials where they would just perish from GBM. What I was hoping for, was your perspective and others who are far more familiar in this area than I, on if this is possible.

But your post about the interpretation of results was extremely helpful.